Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 91

1.

Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study.

Geoerger B, Zwaan CM, Marshall LV, Michon J, Bourdeaut F, Casanova M, Corradini N, Rossato G, Farid-Kapadia M, Shemesh CS, Hutchinson KE, Donaldson F, Liao M, Caron H, Trippett T.

Lancet Oncol. 2019 Nov 25. pii: S1470-2045(19)30693-X. doi: 10.1016/S1470-2045(19)30693-X. [Epub ahead of print]

PMID:
31780255
2.

Neuroblastoma stage 4S: Tumor regression rate and risk factors of progressive disease.

Tas ML, Nagtegaal M, Kraal KCJM, Tytgat GAM, Abeling NGGM, Pluijm SMF, Zwaan CM, de Keizer B, Molenaar JJ, van Noesel MM.

Pediatr Blood Cancer. 2019 Nov 17:e28061. doi: 10.1002/pbc.28061. [Epub ahead of print]

PMID:
31736229
3.

Pharmacokinetics of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia or acute lymphoblastic leukemia.

Hijiya N, Zwaan CM, Rizzari C, Foa R, Abbink F, Lancaster D, Landman-Parker J, Millot F, Moppett J, Nelken B, Caterina Putti M, Tian X, Sinclair K, Santanastasio H, Buchbinder A, Kearns P.

Clin Cancer Res. 2019 Nov 1. pii: clincanres.0090.2019. doi: 10.1158/1078-0432.CCR-19-0090. [Epub ahead of print]

PMID:
31676669
4.

Voluntary Informed Consent Is Not Risk Dependent.

Dekking SAS, van der Graaf R, Zwaan CM, van Delden JJM.

Am J Bioeth. 2019 Apr;19(4):33-35. doi: 10.1080/15265161.2019.1572820. No abstract available.

PMID:
31544669
5.

Epigenetic drug screen identifies the histone deacetylase inhibitor NSC3852 as a potential novel drug for the treatment of pediatric acute myeloid leukemia.

Wiggers CRM, Govers AMAP, Lelieveld D, Egan DA, Zwaan CM, Sonneveld E, Coffer PJ, Bartels M.

Pediatr Blood Cancer. 2019 Aug;66(8):e27785. doi: 10.1002/pbc.27785. Epub 2019 May 1.

PMID:
31044544
6.

A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia.

Arrieta AC, Sung L, Bradley JS, Zwaan CM, Gates D, Waskin H, Carmelitano P, Groll AH, Lehrnbecher T, Mangin E, Joshi A, Kartsonis NA, Walsh TJ, Paschke A.

PLoS One. 2019 Mar 26;14(3):e0212837. doi: 10.1371/journal.pone.0212837. eCollection 2019.

7.

ALK inhibition in two emblematic cases of pediatric inflammatory myofibroblastic tumor: Efficacy and side effects.

Brivio E, Zwaan CM.

Pediatr Blood Cancer. 2019 May;66(5):e27645. doi: 10.1002/pbc.27645. Epub 2019 Jan 29.

PMID:
30697903
8.

CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping.

Bras AE, de Haas V, van Stigt A, Jongen-Lavrencic M, Beverloo HB, Te Marvelde JG, Zwaan CM, van Dongen JJM, Leusen JHW, van der Velden VHJ.

Cytometry B Clin Cytom. 2019 Mar;96(2):134-142. doi: 10.1002/cyto.b.21745. Epub 2018 Nov 18.

9.

The genetic basis and cell of origin of mixed phenotype acute leukaemia.

Alexander TB, Gu Z, Iacobucci I, Dickerson K, Choi JK, Xu B, Payne-Turner D, Yoshihara H, Loh ML, Horan J, Buldini B, Basso G, Elitzur S, de Haas V, Zwaan CM, Yeoh A, Reinhardt D, Tomizawa D, Kiyokawa N, Lammens T, De Moerloose B, Catchpoole D, Hori H, Moorman A, Moore AS, Hrusak O, Meshinchi S, Orgel E, Devidas M, Borowitz M, Wood B, Heerema NA, Carrol A, Yang YL, Smith MA, Davidsen TM, Hermida LC, Gesuwan P, Marra MA, Ma Y, Mungall AJ, Moore RA, Jones SJM, Valentine M, Janke LJ, Rubnitz JE, Pui CH, Ding L, Liu Y, Zhang J, Nichols KE, Downing JR, Cao X, Shi L, Pounds S, Newman S, Pei D, Guidry Auvil JM, Gerhard DS, Hunger SP, Inaba H, Mullighan CG.

Nature. 2018 Oct;562(7727):373-379. doi: 10.1038/s41586-018-0436-0. Epub 2018 Sep 12.

10.

A phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia.

Zwaan CM, Söderhäll S, Brethon B, Luciani M, Rizzari C, Stam RW, Besse E, Dutreix C, Fagioli F, Ho PA, Dufour C, Pieters R.

Br J Haematol. 2019 May;185(3):623-627. doi: 10.1111/bjh.15593. Epub 2018 Sep 11. No abstract available.

PMID:
30203832
11.

Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group.

Noort S, Zimmermann M, Reinhardt D, Cuccuini W, Pigazzi M, Smith J, Ries RE, Alonzo TA, Hirsch B, Tomizawa D, Locatelli F, Gruber TA, Raimondi S, Sonneveld E, Cheuk DK, Dworzak M, Stary J, Abrahamsson J, Arad-Cohen N, Czogala M, De Moerloose B, Hasle H, Meshinchi S, van den Heuvel-Eibrink M, Zwaan CM.

Blood. 2018 Oct 11;132(15):1584-1592. doi: 10.1182/blood-2018-05-849059. Epub 2018 Aug 27.

12.

Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study.

Flasinski M, Scheibke K, Zimmermann M, Creutzig U, Reinhardt K, Verwer F, de Haas V, van der Velden VHJ, von Neuhoff C, Zwaan CM, Reinhardt D, Klusmann JH.

Blood Adv. 2018 Jul 10;2(13):1532-1540. doi: 10.1182/bloodadvances.2018018945.

13.

Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study.

van Eijkelenburg NKA, Rasche M, Ghazaly E, Dworzak MN, Klingebiel T, Rossig C, Leverger G, Stary J, De Bont ESJM, Chitu DA, Bertrand Y, Brethon B, Strahm B, van der Sluis IM, Kaspers GJL, Reinhardt D, Zwaan CM.

Haematologica. 2018 Sep;103(9):1484-1492. doi: 10.3324/haematol.2017.187153. Epub 2018 May 17.

14.

RNA-based FLT3-ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML.

Cucchi DGJ, Denys B, Kaspers GJL, Janssen JJWM, Ossenkoppele GJ, de Haas V, Zwaan CM, van den Heuvel-Eibrink MM, Philippé J, Csikós T, Kwidama Z, de Moerloose B, de Bont ESJM, Lissenberg-Witte BI, Zweegman S, Verwer F, Vandepoele K, Schuurhuis GJ, Sonneveld E, Cloos J.

Blood. 2018 May 31;131(22):2485-2489. doi: 10.1182/blood-2017-12-819508. Epub 2018 Apr 18.

PMID:
29669779
15.

Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies.

Place AE, Goldsmith K, Bourquin JP, Loh ML, Gore L, Morgenstern DA, Sanzgiri Y, Hoffman D, Zhou Y, Ross JA, Prine B, Shebley M, McNamee M, Farazi T, Kim SY, Verdugo M, Lash-Fleming L, Zwaan CM, Vormoor J.

Future Oncol. 2018 Sep;14(21):2115-2129. doi: 10.2217/fon-2018-0121. Epub 2018 Mar 29.

16.

Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial.

Gore L, Kearns PR, de Martino ML, Lee, De Souza CA, Bertrand Y, Hijiya N, Stork LC, Chung NG, Cardos RC, Saikia T, Fagioli F, Seo JJ, Landman-Parker J, Lancaster D, Place AE, Rabin KR, Sacchi M, Swanink R, Zwaan CM.

J Clin Oncol. 2018 May 1;36(13):1330-1338. doi: 10.1200/JCO.2017.75.9597. Epub 2018 Mar 2.

17.

Endogenous Tumor Suppressor microRNA-193b: Therapeutic and Prognostic Value in Acute Myeloid Leukemia.

Bhayadia R, Krowiorz K, Haetscher N, Jammal R, Emmrich S, Obulkasim A, Fiedler J, Schwarzer A, Rouhi A, Heuser M, Wingert S, Bothur S, Döhner K, Mätzig T, Ng M, Reinhardt D, Döhner H, Zwaan CM, van den Heuvel Eibrink M, Heckl D, Fornerod M, Thum T, Humphries RK, Rieger MA, Kuchenbauer F, Klusmann JH.

J Clin Oncol. 2018 Apr 1;36(10):1007-1016. doi: 10.1200/JCO.2017.75.2204. Epub 2018 Feb 12.

PMID:
29432078
18.

Leukaemic stem cell load at diagnosis predicts the development of relapse in young acute myeloid leukaemia patients.

Hanekamp D, Denys B, Kaspers GJL, Te Marvelde JG, Schuurhuis GJ, De Haas V, De Moerloose B, de Bont ES, Zwaan CM, de Jong A, Depreter B, Lammens T, Philippé J, Cloos J, van der Velden VHJ.

Br J Haematol. 2018 Nov;183(3):512-516. doi: 10.1111/bjh.14991. Epub 2017 Oct 26. No abstract available.

PMID:
29076143
19.

Correction to: A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma.

Veldhuijzen van Zanten SEM, El-Khouly FE, Jansen MHA, Bakker DP, Sanchez Aliaga E, Haasbeek CJA, Wolf NI, Zwaan CM, Vandertop WP, van Vuurden DG, Kaspers GJL.

J Neurooncol. 2018 Jan;136(1):219-220. doi: 10.1007/s11060-017-2636-0.

20.

Clinical trial simulations in paediatric oncology: A feasibility study from the Innovative Therapies for Children with Cancer Consortium.

Janssen JM, Zwaan CM, Schellens JHM, Beijnen JH, Huitema ADR.

Eur J Cancer. 2017 Nov;85:78-85. doi: 10.1016/j.ejca.2017.07.050. Epub 2017 Sep 9.

PMID:
28892776

Supplemental Content

Loading ...
Support Center